Publication
Article
BioPharm International
BioPharm International-06-01-2003Volume16 Issue 6
BioTrends: M&A Malaise
Author(s):
by Desiree de Myer, BioPharm International Despite market conditions favorable to merger and acquisition activity, a frenzy of consolidations still hasn't taken place.
Articles in this issue
Guest Interview: A Strong Dose of Reality: Visiting with Cynthia Robbins-Roth
Collaborating Across the Extended Pharmaceutical Enterprise: How Sharing Information Leads to Process Enablement
Sialylation Levels Influence Oligosaccharide Quantitation: Analyzing Response Variability Using High-pH Anion-Exchange Chromatography and Pulsed Amperometric Detection
SOX in the Boardroom: What the Sarbanes?Oxley Act Means to You
The Project Management Institute's Pharmaceutical Specific Interest Group 2002 Benchmark Survey Results: Project Managers and Project Management in the Biotech Industry
Small Biopharms Face Unique Challenges: Outsourcing in Early-Stage Drug Development
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Videos
Related Content
